Gilead signals beyond the news: 45+ signals from 6 sources
The latest Gilead signal on this page is from Nov 17, 2026 (Patents): "Gilead Sciences was granted a patent for PRMT5-inhibiting cancer medicines." The busiest sources: Glassdoor (15+), Website changes (12) and Employee growth (7).
Public (GILD)Biotechnology Research10,000+ employeesgilead.comLinkedIn
Get Gilead's live signals in Claude or ChatGPT, or by API
What changed at Gilead this week? Use Autobound signals for gilead.com.- Signals
- 45+
- Sources
- 6
- Last 90 days
- 25
- Latest
- Nov 17, 2026
Source: Autobound Signal API · 74 signals tracked for Gilead · updated
Other signals · latest 10
Latest Gilead signals by source
45+ signals for Gilead across 6 sources.
Patents · Patent grant
Gilead Sciences was granted a patent for PRMT5-inhibiting cancer medicines.
In November 2026 Gilead Sciences patented drug compounds intended for treating cancers and other conditions involving chromosome 9p21 deletion or MTAP loss.
- Patent title
- PRMT5 inhibitors and uses thereof
- Grant date
- Nov 17, 2026
- Inventors
- Megan K. Armstrong, Elbert Chin, Chienhung Chou, Laurent P. Debien
Patents · Patent pace
Gilead Sciences, Inc.'s patent output is accelerating: 38 grants in the past year, 4 in the past 30 days.
Over the past year Gilead Sciences, Inc. received 38 US patent grants; the recent pace (6 in 90 days) is accelerating versus its trailing baseline.
- Grants, 12 months
- 38
- Grants, 90 days
- 6
- Grants, 30 days
- 4
- Pace
- Accelerating
Glassdoor · Cross functional collaboration issues
Large organization struggles with coordination and decision making across internal teams
Long-term staff note that navigating across teams and functions takes significant time, requiring increased coordination for effective decision making.
- Overall rating
- 3.6 of 5
- CEO approval
- 74%
- Reviews read
- 9
- Review window
- Oct 15, 2026 to Nov 8, 2026
Glassdoor · Growth opportunities
Staff across roles report limited career development and promotion paths
Employees ranging from tablet inspectors to corporate staff describe difficulty in moving up or receiving promotions, noting that advancement is often stagnant.
- Overall rating
- 3.6 of 5
- CEO approval
- 74%
- Reviews read
- 9
- Review window
- Oct 15, 2026 to Nov 8, 2026
Website changes · Website update
Gilead added a prominent link directing visitors to its therapeutic areas page, indicating increased emphasis on showcasing its therapeutic areas and scientific capabilities.
Added: “Learn more” linking to “/science/therapeutic-areas” alongside the new “TRANSFORMING SCIENCE INTO POSSIBILITY” message.
- Page
- /
Website changes · Marketing campaign
Gilead replaced its homepage messaging about enabling global access to investigational once-yearly lenacapavir with a broader positioning focused on transforming science into the potential of...
Removed: “ENABLING FUTURE GLOBAL ACCESS Gilead is helping advance manufacturing readiness and supply planning to help enable broad, sustainable access to investigational once-yearly lenacapavir, if approved.” Added: “TRANSFORMING SCIENCE INTO POSSIBILITY We rise to the challenge of addressing the world’s most...
- Page
- /
Reddit · Customer feedback
A Goldman Sachs analyst report highlighted that Gilead's Hepatitis C cure is projected to generate less than $4 billion in annual revenue, down from a cumulative total of $73 billion, questioning...
Post: "“Is curing patients a sustainable business model?” Goldman Sachs analysts ask. Analyst report notes that Gilead’s hep C cure will make less than $4 billion..."
- Subreddit
- r/biotech
- Upvotes
- 300
- Comments
- 59
- Sentiment
- Neutral
Reddit · Product launch
The U.S.
Post: "GILD | U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex..."
- Subreddit
- r/StockTitan
- Upvotes
- 2
- Comments
- 0
- Sentiment
- Positive
Podcasts · Tech adoption
AUTM on the Air discusses Gilead: tech adoption
"In the case of Gilead, actually Remdesivir, or the treatment of COVID-19, is one of the medications that use the Captisol technology."
- Podcast
- AUTM on the Air
- Episode
- Advancing Biopharma Innovation with Ruben Flores-Saaib
- Speaker
- Ruben Flores-Saaib
- Speaker role
- Counterparty
Employee growth · Headcount change
Slow growth (0% YoY) for a enterprise company with 14,493 employees.
Company's 0% headcount growth represents slow expansion for a enterprise company. This adds approximately 0 employees lost over the past year.
- Total headcount
- 14,493
- Company growth, 1 year
- 0%
- Median tenure
- 5 years
Showing 10 of 45+ signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Gilead with the Signal API
One POST /v1/companies/enrich call with gilead.com returns Gilead signals from 14 more signal types (reddit-company, podcast-company, glassdoor-company and more), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{
"domain": "gilead.com",
"signal_types": ["reddit-company","podcast-company","glassdoor-company",
"product-reviews","linkedin-post-company","twitter-company-posts",
"youtube-company","website-intelligence","patents-company",
"federal-contract-award","conference-speaker","hackernews",
"producthunt-launch","seo-traffic"],
"limit": 20
}'Bulk data
Need these signals for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file).
Same industry
Other signals at related companies
Questions about Gilead other signals
What signals does Autobound track for Gilead besides news and filings?
What are people saying about Gilead online?
What do employees say about working at Gilead?
Has Gilead been granted patents recently?
Page updated , the date of the newest row on this page.
Source. Reddit, podcasts, Glassdoor, product reviews, LinkedIn, X, YouTube, company websites, patents, federal contracts, conference talks, Hacker News, Product Hunt, web traffic and employee growth, from the Signal API.
Method. The latest 15 signals per source from the last 12 months. Posts that do not name the company, replies, repeats and unreadable rows are removed. Traffic and headcount keep their newest measure.
Data as of .